-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Wqc9InZGSxsme3cWDjIbA4bDsz8e8fR8lzAYdiQdstWusD4s9UI3+Q3+CAZNfjKm JjLlX/ckWW//ThGHs6shaA== 0001179110-03-010462.txt : 20031112 0001179110-03-010462.hdr.sgml : 20031111 20031112082051 ACCESSION NUMBER: 0001179110-03-010462 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20031107 FILED AS OF DATE: 20031112 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ABIOMED INC CENTRAL INDEX KEY: 0000815094 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042743260 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 22 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RABE EUGENE D CENTRAL INDEX KEY: 0001199634 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09585 FILM NUMBER: 03990601 BUSINESS ADDRESS: STREET 1: C/O ABIOMED INC STREET 2: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: C/O ABIOMED INC STREET 2: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 4 1 edgar.xml FORM 4 - X0201 4 2003-11-07 0 0000815094 ABIOMED INC ABMD 0001199634 RABE EUGENE D C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS MA 01923 0 1 0 0 SVP, Global Sales & Services Common Stock, $.01 par value 2003-11-07 4 M 0 400 4.00 A 400 D Common Stock, $.01 par value 2003-11-07 4 S 0 400 8.66 D 0 D Stock Option (right to buy) 4.00 2003-11-07 4 M 0 400 0 D 1998-11-15 2003-11-15 Common Stock 22200 21800 D Stock Option (right to buy) 5.313 2000-12-14 2005-12-14 Common Stock 50000 50000 D Stock Option (right to buy) 6.25 2001-08-12 2006-08-12 Common Stock 40000 40000 D Stock Option (right to buy) 5.75 2002-05-27 2007-05-27 Common Stock 15000 15000 D Stock Option (right to buy) 6.813 2000-07-01 2008-07-01 Common Stock 35000 35000 D Stock Option (right to buy) 6.688 2001-07-01 2009-07-01 Common Stock 30000 30000 D Stock Option (right to buy) 15.563 2002-06-28 2010-06-28 Common Stock 40000 40000 D Stock Option (right to buy) 24.12 2003-06-22 2011-06-22 Common Stock 20000 20000 D Stock Option (right to buy) 6.75 2004-06-25 2012-06-25 Common Stock 50000 50000 D Stock Option (right to buy) 5.11 2005-06-25 2013-06-25 Common Stock 20000 20000 D Options were fully exercisable on the date shown. Grant to reporting person of this option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 1992 Combination Stock Option Plan. Grant to reporting person of this option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 1998 Equity Incentive Plan. Grant to reporting person of this option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan. The option becomes exercisable in annual 25% installments commencing on the date shown in Table II, Column 6. Thirty percent of this option will become exercisable on each of 7/1/01 and 7/1/02 and an additional 40 percent will become exercisable on 7/1/03. Thirty percent of this option will become exercisable on each of 6/28/02 and 6/28/03 and an additional 40 percent will become exercisable on 6/28/04. Thirty percent of this option will become exercisable on each of 6/22/03 and 6/22/04 and an additional 40 percent will become exercisable on 6/22/05. Thirty percent of this option will become exercisable on each of 6/25/04 and 6/25/05 and an additional 40 percent will become exercisable on 6/25/06. Thirty percent of this option will become exercisable on each of 6/25/05 and 6/25/06 and an additional 40 percent will become exercisable on 6/25/07. Stock was acquired and sold pursuant to a Sales Plan compliant with the requirements of SEC Rule 10b5-1. /s/ Eugene D. Rabe 2003-11-10 -----END PRIVACY-ENHANCED MESSAGE-----